AlphaQuest’s ArriVent BioPharma AVBP Stock Holding History

AlphaQuest’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,800	Closed	-$56.3K	–	2160
2025 Q4	$56.3K	Sell	2,800 -38,649	-93%	-$804K	﹤0.01%	1910
2025 Q3	$765K	Buy	+41,449	New	+$814K	0.05%	553

Other funds holding AVBP

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AlphaQuest's AVBP Position: Q1 2026 in Review

AlphaQuest sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 2,800 shares — an estimated $56.3K sold.

AlphaQuest first reported a position in AVBP in Q3 2025 and held it in 2 quarters. The position peaked at $765K in Q3 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

AlphaQuest reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 2,800 ArriVent BioPharma shares in Q1 2026, an estimated $56.3K.
AlphaQuest first reported a position in ArriVent BioPharma in Q3 2025 and held it in 2 quarters.
AlphaQuest's ArriVent BioPharma position peaked at $765K in Q3 2025.
139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.